CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Tarsus bets $450M on Alkeus’ Stargardt drug

Positive
AI Analysis

Summary

Tarsus Pharmaceuticals is acquiring Phase 3 biotech Alkeus Pharmaceuticals for $450 million upfront to expand its ophthalmology portfolio with Alkeus' Stargardt disease drug candidate.

Clinical Trial Data

Phase

Phase 3

Importance:7/10
Sentiment:
0.60
M&AophthalmologyPhase 3Stargardt diseaseacquisition
Related Companies

Read the original article

Published by Endpoints News on August 6, 2026 12:57 PM

Read Original